Table 2.
Treatment of endometriosis patients in the 1 year post hysterectomy or laparoscopy
| By 3 months* | By 6 months* | By 12 months* | ||||
|---|---|---|---|---|---|---|
| Endometriosis patients with hysterectomy N = 24,915 | Endometriosis patients with laparoscopy N = 37,308 | Endometriosis patients with hysterectomy N = 24,915 | Endometriosis patients with laparoscopy N = 37,308 | Endometriosis patients with hysterectomy N = 24,915 | Endometriosis patients with laparoscopy N = 37,308 | |
| Medical treatment, n (%) | ||||||
| Combined oral contraceptives and NSAIDs | 9047 (36.3%) | 10,052 (26.9%) | 10,110 (40.6%) | 13,325 (35.7%) | 11,741 (47.1%) | 18,088 (48.5%) |
| Combined oral contraceptives | 142 (0.6%) | 5825 (15.6%) | 182 (0.7%) | 7353 (19.7%) | 259 (1.0%) | 9399 (25.2%) |
| NSAIDs | 8977 (36.0%) | 5297 (14.2%) | 10,026 (40.2%) | 7857 (21.1%) | 11,636 (46.7%) | 12,258 (32.9%) |
| Analgesics—opioid a | – | – | 4398 (17.7%)NS | 6785 (18.2%)NS | 8243 (33.1%) | 13,644 (36.6%) |
| Analgesics—non-opioid a | – | – | 366 (1.5%)NS | 488 (1.3%)NS | 767 (3.1%)NS | 1096 (2.9%)NS |
| GnRH agonists | 63 (0.3%) | 2800 (7.5%) | 82 (0.3%) | 3506 (9.4%) | 120 (0.5%) | 4333 (11.6%) |
| Leuprolide | 61 (0.2%) | 2696 (7.2%) | 80 (0.3%) | 3386 (9.1%) | 116 (0.5%) | 4189 (11.2%) |
| Other GnRHs | 2 (0.0%) | 108 (0.3%) | 2 (0.0%) | 128 (0.3%) | 4 (0.0%) | 158 (0.4%) |
| Progestin | 416 (1.7%) | 4492 (12.0%) | 526 (2.1%) | 6302 (16.9%) | 739 (3.0%) | 8495 (22.8%) |
| DMPA | 29 (0.1%) | 517 (1.4%) | 41 (0.2%) | 673 (1.8%) | 56 (0.2%) | 948 (2.5%) |
| Other progestins | 389 (1.6%) | 4006 (10.7%) | 488 (2.0%) | 5691 (15.3%) | 687 (2.8%) | 7728 (20.7%) |
| Danazol | 2 (0.0%) | 39 (0.1%) | 2 (0.0%) | 50 (0.1%) | 8 (0.0%) | 69 (0.2%) |
NS not statistically different between hysterectomy and laparoscopy cohorts, DMPA depot medroxyprogesterone acetate
* All differences between hysterectomy and laparoscopy cohorts statistically significant on the basis of Chi square tests unless otherwise noted by NS
aEndometriosis-related analgesic use defined as any use received after 90 days of index surgery